CN110483522B - 氘化杂环化合物和其作为成像剂的用途 - Google Patents

氘化杂环化合物和其作为成像剂的用途 Download PDF

Info

Publication number
CN110483522B
CN110483522B CN201910795177.8A CN201910795177A CN110483522B CN 110483522 B CN110483522 B CN 110483522B CN 201910795177 A CN201910795177 A CN 201910795177A CN 110483522 B CN110483522 B CN 110483522B
Authority
CN
China
Prior art keywords
compound
certain embodiments
imaging
compounds
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910795177.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110483522A (zh
Inventor
扬·马里克
约瑟夫·P·利丝卡托斯
西蒙·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN110483522A publication Critical patent/CN110483522A/zh
Application granted granted Critical
Publication of CN110483522B publication Critical patent/CN110483522B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201910795177.8A 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途 Active CN110483522B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
US61/992,717 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents
CN201580025219.XA CN106459059B (zh) 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580025219.XA Division CN106459059B (zh) 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途

Publications (2)

Publication Number Publication Date
CN110483522A CN110483522A (zh) 2019-11-22
CN110483522B true CN110483522B (zh) 2022-05-03

Family

ID=53269446

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910795177.8A Active CN110483522B (zh) 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途
CN201580025219.XA Active CN106459059B (zh) 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580025219.XA Active CN106459059B (zh) 2014-05-13 2015-05-12 氘化杂环化合物和其作为成像剂的用途

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3143011B1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102530129B1 (enExample)
CN (2) CN110483522B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX376163B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG10201805628TA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3143011T1 (sl) * 2014-05-13 2021-08-31 F. Hoffmann-La Roche Ag Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
IL264239B (en) 2016-07-22 2022-08-01 Ac Immune Sa Compounds for imaging tau protein aggregates
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
EP3758696B1 (en) 2018-03-02 2026-02-25 The Trustees of the University of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
US11325912B2 (en) 2019-05-09 2022-05-10 Genentech, Inc. Regio-selective synthesis of imidazo[1,2-a]pyrimidines
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
WO2023245008A1 (en) 2022-06-13 2023-12-21 Genentech, Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182812A1 (en) * 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (enExample) *
EP1340759A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
ES2628882T3 (es) * 2006-03-30 2017-08-04 The Trustees Of The University Of Pennsylvania Derivados de estirilpiridina, y su uso para unir y formar imágenes de placas amiloides
JP5647519B2 (ja) * 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
KR101609504B1 (ko) * 2012-05-22 2016-04-05 일라이 릴리 앤드 캄파니 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제
NO3055308T3 (enExample) * 2013-10-08 2018-04-21
SI3143011T1 (sl) 2014-05-13 2021-08-31 F. Hoffmann-La Roche Ag Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182812A1 (en) * 2009-03-23 2011-07-28 Siemens Medical Solutions Usa, Inc. Imaging Agents for Detecting Neurological Disorders
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2012065963A2 (en) * 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Development of a novel fluorine-18 labeled deuterated fluororasagiline ([18F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B);S. Nag等;《Bioorganic & Medicinal Chemistry》;20130815;第21卷(第22期);全文 *
Evaluation of Deuterated 18F- and 11C-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography;Timothy H. Witney等;《Clin Cancer Res》;20120110;第18卷(第4期);1-7 *
氘代作用在药物研究中的应用;江文峰等;《齐鲁药事》;20101231;第29卷(第11期);全文 *

Also Published As

Publication number Publication date
ES2867814T3 (es) 2021-10-20
US20160250358A1 (en) 2016-09-01
CN106459059B (zh) 2019-09-24
AU2019203369A1 (en) 2019-06-06
WO2015173225A1 (en) 2015-11-19
RU2016147742A3 (enExample) 2018-10-08
BR112016026443A8 (pt) 2021-07-06
HUE053939T2 (hu) 2021-08-30
JP2017515856A (ja) 2017-06-15
CN110483522A (zh) 2019-11-22
RU2016147742A (ru) 2018-06-18
US20200297875A1 (en) 2020-09-24
IL280791A (en) 2021-04-29
US20190201561A1 (en) 2019-07-04
JP6529986B2 (ja) 2019-06-12
IL280791B1 (en) 2023-11-01
CA2948721A1 (en) 2015-11-19
PT3143011T (pt) 2021-04-26
MX2016014615A (es) 2017-03-06
JP2019147825A (ja) 2019-09-05
LT3143011T (lt) 2021-05-10
EP3143011A1 (en) 2017-03-22
NZ726208A (en) 2023-11-24
EP3143011B1 (en) 2021-03-03
SI3143011T1 (sl) 2021-08-31
KR20170002639A (ko) 2017-01-06
US10675367B2 (en) 2020-06-09
AU2019203369B2 (en) 2020-06-04
CA2948721C (en) 2023-03-28
MX384604B (es) 2025-03-14
US11504440B2 (en) 2022-11-22
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
CN106459059A (zh) 2017-02-22
IL248692A0 (en) 2017-01-31
IL271631B (en) 2021-05-31
KR20230035445A (ko) 2023-03-13
KR102618139B1 (ko) 2023-12-27
AU2015261008A1 (en) 2016-11-17
IL280791B2 (en) 2024-03-01
IL271631A (en) 2020-02-27
US10076581B2 (en) 2018-09-18
IL248692B (en) 2020-01-30
KR102530129B1 (ko) 2023-05-10
AU2015261008B2 (en) 2019-02-14
PL3143011T3 (pl) 2021-07-19
SG11201609281UA (en) 2016-12-29
NZ764181A (en) 2023-11-24
JP6681498B2 (ja) 2020-04-15
HRP20210641T1 (hr) 2021-05-28
DK3143011T3 (da) 2021-05-03
US12214058B2 (en) 2025-02-04
MX376163B (es) 2025-03-07
US20230218782A1 (en) 2023-07-13
RS61810B1 (sr) 2021-06-30
MX2020010847A (es) 2021-07-16
EP3901145A1 (en) 2021-10-27
BR112016026443A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
US12214058B2 (en) Imaging methods using deuterated compounds
EP3186241B1 (en) Probes for imaging huntington protein
TW201018678A (en) Novel heteroaryl substituted benzothiazoles
BRPI0806621A2 (pt) composto, uso de um composto, composição farmacêutica, e, método in vivo para medir depósitos amilóides em um indivìduo
EP3728234A1 (en) Radiolabeled compounds
AU2015308769A1 (en) Probes for imaging huntingtin protein
HK40014375A (en) Deuterated heterocyclic compounds and their use as imaging agents
HK40014375B (zh) 氘化杂环化合物和其作为成像剂的用途
RU2791900C1 (ru) Дейтрированные гетероциклические соединения и их применение в качестве средств визуализации
HK1228902A1 (en) Deuterated heterocyclic compounds and their use as imaging agents
HK1228902B (zh) 氘化杂环化合物和其作为成像剂的用途
BR112016026443B1 (pt) Compostos heterocíclicos deuterados, seus usos, e composição farmacêutica
HK1240582A1 (en) Probes for imaging huntington protein
HK1240582B (en) Probes for imaging huntington protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014375

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant